This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Merck KGaA, Darmstadt, Germany.
Reference
Stintzing S, et al. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. Journal of Medical Economics : 4 Jan 2020. Available from: URL: https://doi.org/10.1080/13696998.2019.1709848
Rights and permissions
About this article
Cite this article
FOLFIRI + cetuximab cost effective in RAS wild-type metastatic CRC. PharmacoEcon Outcomes News 845, 10 (2020). https://doi.org/10.1007/s40274-020-6513-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6513-2